Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. [electronic resource]
Producer: 20080214Description: 597-604 p. digitalISSN:- 1538-7445
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis -- drug effects
- B-Lymphocytes -- drug effects
- CHO Cells
- Cricetinae
- Cricetulus
- Fas Ligand Protein -- agonists
- Female
- Genetic Therapy -- adverse effects
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell -- genetics
- Lymphoma, Non-Hodgkin -- genetics
- Male
- Recombinant Fusion Proteins -- adverse effects
- Rituximab
- Signal Transduction -- drug effects
- Single-Chain Antibodies
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Comparative Study; Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.